StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report released on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food and Drug Administration to help treat depression, Johnson & Johnson announced on Tuesday. Spravato is a first-of-its-kind ...

Nasal sprays are available by prescription or over the counter (OTC). Most products come in a hand-operated pump bottle or squeeze bottle. Knowing how to use a nasal spray is important, as doing it ...

GIMOTI® (metoclopramide) nasal spray remains the sole FDA-approved treatment for diabetic gastroparesis, providing effective symptom relief and substantial cost savings compared to oral ...

(NASDAQ: EVOK), a specialty Pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, underscores its ...

SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an ...